Oct. 8, 2004 -- A bipartisan group of lawmakers are accusing the Bush administration of moving too slowly on proposed new safety measures for the acne drug Accutane and are calling for the drug to be pulled from the U.S. market.
The lawmakers say the FDA has not acted on February recommendations from an expert advisory panel urging the agency to implement stricter patient tracking rules for patients who use Accutane. Several are threatening to insert legislation restricting Accutane's use into a federal spending bill if action is not taken by Nov. 1.
Accutane has been the subject of public scrutiny in recent years because of several health concerns, including an increased risk of birth defects in children born to women who take it while pregnant and a possible risk of depression and suicide in adolescents.
An expert panel urged the FDA in February to come up with stricter rules for tracking women of childbearing age in an effort to prevent them from becoming pregnant while taking Accutane. Experts recommended at that time the use of a mandatory patient registry and required patient education for everyone who uses Accutane for severe acne. But the agency has so far failed to act on the recommendations.
"There shouldn't be a lag time when you're talking about life and death of young people," says Rep. Bart Stupak (D-Mich.). "It's a very serious health issue, and we wish they'd treat it that way."
Stupak and three Republican lawmakers sent a letter earlier this week to Health and Human Services Secretary Tommy G. Thompson criticizing the FDA for moving slowly on new Accutane rules and urging the agency to pull the drug off the market until action is taken.
The letter points to a small study conducted at Emory University in Atlanta showing that Accutane can affect brain metabolism. Stupak, who's 17-year-old son committed suicide four years ago while taking Accutane, says the study is evidence that the drug has potential to play a role in depression or suicide.
"We all realize that more research is needed; but we cannot allow this drug to continue on the market, prescribed at a rate of 1.8 million prescriptions annually, when it may affect the brain of young people," the letter states.